Core Viewpoint - The domestic R&D demand is showing marginal improvement, driven by the overseas expansion of innovative drugs, leading to a recovery in R&D orders and stabilization of industry prices after a decline in 2023. The CRO sector is expected to see better performance growth by 2026, while the CDMO industry has also reached a bottom and is poised for continued strong growth due to robust demand for new molecules and new orders [1][2][3]. CRO Sector - The domestic R&D demand is recovering, with an increase in orders and stabilization of prices, indicating a clear upward trend for CRO companies. Clinical CROs like Tigermed, Nossan, and Prasis are expected to see revenue growth turning positive by 2025, with significant contributions from overseas business [2][3]. - The recognition of domestic CRO clinical data is improving, which is beneficial for companies like Tigermed [2]. CDMO Sector - The CDMO sector has seen a recovery in performance, with new orders continuing to improve quarterly. The global demand for innovative drug R&D is driving growth in new orders and backlog [3]. - The industry is benefiting from increased capacity utilization and profitability, with a strong certainty of performance and profit growth expected to continue into 2026 [3]. Life Sciences Sector - The life sciences upstream sector is experiencing a dual drive from domestic substitution and overseas expansion, with urgent demand for domestic alternatives in areas like cell culture media and biological reagents. Companies are expected to capture market share through new product categories and cost-effective offerings [4]. - The demand for specific segments such as drug efficacy, antibodies, and proteins is increasing, indicating a clear long-term growth logic for the industry [4]. API Sector - The raw material pharmaceutical industry is currently in a phase of price bottoming and supply surplus, with traditional product performance under pressure. However, companies are extending their business into generics, innovative drugs, and specialty APIs, which may lead to value reconstruction through business structure optimization [5]. - The valuation of raw material pharmaceutical companies is at a low point, presenting opportunities based on changes in new business layouts [5]. Investment Recommendations - For clinical and preclinical CROs, companies like Tigermed, Nossan, and Yinos are recommended due to the gradual recovery of the industry and expected improvement in order structure [6]. - In the CDMO sector, companies such as WuXi AppTec, WuXi Biologics, and others with strong fundamentals and capacity advantages are highlighted for their potential benefits from industry recovery and high demand for new molecules [6]. - In the life sciences upstream sector, companies like Baitai Biotechnology and others are recommended due to accelerated domestic substitution and strong overseas growth [6]. - Companies like Pro Pharma and Huahai Pharmaceutical are noted for their new business layouts that are expected to contribute significant value increments [6].

新京报贝壳财经讯 11月19日，普洛药业发布公告称，公司拟使用自有资金及金融机构回购贷款通过深 圳证券交易所交易系统以集中竞价交易方式回购公司股份，回购股份价格不超过23元/股，回购资金总 额为不低于1.8亿元（含）且不超过3.6亿元（含）；预计可回购股份数量为783万股—1565万股，约占公 司总股本的0.68%—1.35%。回购期限为自董事会审议通过回购股份方案之日起12个月内。若公司在股 份回购完成后36个月内未能实施前述用途，未使用部分将依法履行相关程序后予以注销。 编辑 杨娟娟 ...

Core Viewpoint - The article highlights the positive outlook for the Chinese stock market, with foreign institutions increasing their investments and adjusting target indices upward for 2026, indicating a strong long-term investment potential in A-shares [1][2]. Group 1: Market Performance - As of November 20, 2025, the CSI 500 Quality Growth Index rose by 0.15%, with notable increases in constituent stocks such as Bluestar Technology (up 3.44%) and China National Materials (up 2.31%) [1]. - The CSI 500 Quality Growth ETF (560500) also saw a rise of 0.17%, reflecting overall positive market sentiment [1]. Group 2: Foreign Investment Trends - Multiple foreign institutions, including UBS and Morgan Stanley, have released optimistic reports for the Chinese stock market, collectively raising their target index levels for 2026 [1][2]. - Foreign institutional research and investment activities have been robust, with over 1,300 instances of foreign institutions conducting research on A-share companies since the beginning of the fourth quarter [1]. Group 3: Policy Developments - The China Securities Regulatory Commission (CSRC) has issued a plan to optimize the Qualified Foreign Institutional Investor (QFII) system, aiming to enhance cross-border investment facilitation [2]. - The ongoing improvements in the QFII system are expected to create a more stable and transparent environment for foreign investments in the Chinese capital market [2]. Group 4: Index Composition - The CSI 500 Quality Growth Index comprises 100 high-profitability, sustainable earnings, and cash-rich growth companies selected from the CSI 500 Index [2]. - As of October 31, 2025, the top ten weighted stocks in the index accounted for 21.64% of the total index weight, with companies like Huagong Technology and Kaiying Network being significant constituents [2].

Key Highlights - CICC plans to absorb and merge with Dongxing Securities and Xinda Securities, with stock suspension starting from November 20 [1] - Saiwu Technology has delivered a small batch of perovskite stacked component light-transmitting film, with minimal impact on performance [1] - Zhongfu Industrial intends to invest 259 million yuan in a green manufacturing project for aluminum-based new materials [1] - Dafeng Industrial has won a contract for the construction of stage craft equipment for an international performing arts center, valued at 165 million yuan [2] - Jinbei Automotive plans to invest a total of 158 million yuan to acquire 52% equity in Zhongtuo Technology [1] - Pro Pharmaceutical intends to repurchase shares worth between 180 million and 360 million yuan [1] - Yandong Micro plans to reduce its stake by up to 2.5% through shareholders Jingguorui and the National Integrated Circuit Fund [1][3] - Zhaomin Technology plans to issue convertible bonds to raise no more than 590 million yuan [1] - Dongsoft Group has received a notification from an automotive manufacturer for designated cooperation [1]

黄果指出，国家药监局高度重视集采药品的质量监管，在各方持续努力下，生产供应质量整体稳定可 控。黄果强调，要充分认识保障集采中选药品质量安全的重要性，中选企业要严格落实主体责任，加强 质量控制、药物警戒和信息化追溯等工作，持续合规生产；监管部门将继续实行中选药品生产检查和产 品抽检两个"全覆盖"，并不断优化工作机制，探索开展风险监测等工作，前移监管触角，防范化解风 险，坚决查处违法违规生产经营行为。 这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！ 政策动向 黄果在北京调研集采中选药品质量监管工作 11月18日，国家药监局党组成员、副局长黄果在北京市调研集采中选药品质量监管工作，实地走访华润 双鹤药业股份有限公司，调研企业质量管理及地方药品监管部门监管情况。 汇宇制药：多个产品获得境外上市许可 11月19日，汇宇制药公告称，公司子公司Seacross Pharmaceuticals Ltd.于近期分别收到巴基斯坦药品监 督管理局、英国药品和健康产品管理局和北马其顿药品和医疗设备管理局核准签发的公司产品普乐沙福 注射液、注射用塞替派、注射用阿扎胞苷、注射用唑来膦酸浓溶液 ...

Key Points - CICC plans to absorb and merge with Dongxing Securities and Xinda Securities, with stock suspension starting from November 20 [1] - Saiwu Technology has delivered a small batch of perovskite stacked component light-transmitting films, with minimal impact on performance [1] - Zhongfu Industrial intends to invest 259 million yuan in a green manufacturing project for aluminum-based new materials [1] - Zhaomin Technology plans to issue convertible bonds to raise no more than 590 million yuan [1] - Jinbei Automotive aims to invest a total of 158 million yuan to acquire 52% equity in Zhongtuo Technology [1][2] - Pro Pharmaceutical plans to repurchase company shares worth between 180 million and 360 million yuan [2] - Sudar Co. plans to reduce its stake by no more than 3% [2] - Yandong Micro and the National Integrated Circuit Fund plan to collectively reduce their stake by no more than 2.5% [2] - Fuguang Co.'s controlling shareholder plans to increase its stake by 80 million to 150 million yuan [2] - Dongsoft Group has received a notification from an automotive manufacturer for designated cooperation [1][2]

Group 1: Company Announcements - Aoyuan Meigu has received court approval to continue operations and manage its affairs during the restructuring period, with a risk of bankruptcy and stock delisting if the restructuring fails [3] - Inspur Software reported a net profit of -211.06 million yuan for the first three quarters of 2025, a 123% decline year-on-year, indicating a risk of performance decline [4] - Dayu Water-saving's acquisition of 70% equity in Huai'an Design Institute for 311 million yuan has passed antitrust review, allowing the transaction to proceed [5] - Hainan Development disclosed a cumulative litigation amount of 122 million yuan over the past 12 months, accounting for 11.37% of its latest audited net assets [6] Group 2: Share Buybacks - Haida Group conducted its first share buyback, repurchasing 137,600 shares for a total of approximately 7.99 million yuan [8] - Guangyu Group completed a share buyback of 10,108,000 shares, totaling 29.99 million yuan, representing 1.31% of its total share capital [9] - Puluo Pharmaceutical plans to repurchase shares worth 180 million to 360 million yuan for employee incentive plans, with a maximum price of 23 yuan per share [10] - Huarong Co. executed its first share buyback, acquiring 100,000 shares for a total of 1.89 million yuan [11] Group 3: Shareholding Changes - Kanglongda's major shareholder plans to reduce its stake by up to 3% within 90 days starting December 11, 2025 [12] - Liyuan Technology's shareholder intends to reduce its stake by up to 2.0303% between December 12, 2025, and March 11, 2026 [13] - Yinlong Co.'s controlling shareholder reduced its stake, bringing the total holding down to 25% [14] - Bicheng Co. announced multiple shareholders' plans to reduce their stakes, with specific amounts disclosed [15] Group 4: Major Contracts - Han Jian Heshan won a bid for a water supply project with a contract value of 388 million yuan, expected to significantly impact its revenue [17] - Dafeng Industrial secured a project worth 165 million yuan, representing 8.97% of its 2024 revenue, which could have a long-term positive effect on its performance [18] - Jiangnan Water signed a contract worth 368 million yuan for a drainage project, which is anticipated to positively influence its business performance [19]

1、中金公司：拟换股吸收合并东兴证券、信达证券 11月20日起停牌 重要程度：★★★★★ 中金公司公告称，公司与东兴证券、信达证券正在筹划由中金公司通过换股方式吸收合并东兴证券、信达 证券。为保证公平信息披露，维护投资者利益，避免造成公司股价异常波动，公司A股股票将于2025年11 月20日开市时起停牌，预计停牌时间不超过25个交易日。 从规模来看，Wind显示，中金公司+东兴证券+信达证券三家公司截至2025年三季度末的总资产合计为 10095.83亿元(7649.41亿元+1163.91亿元+1282.51亿元)；净资产合计为1746.81亿元(1178.2亿元+272.21亿元 +296.4亿元)。 业内人士表示，在政策支持下，预计未来券业并购重组案例将会增多，资源整合或将成为券商快速提升规 模与综合实力的重要方式。此外，并购模式的多元化趋势一定程度反映出券业并购已从简单的规模扩张转 向聚焦能力跃迁。 点评：券商真的是在无人问津时难受煎熬处出利好了。希望后续能带领一众券商互联网金融来一波拉升， 不要只拉银行保险这种大块头，给点甜头大家一起实现共赢众乐乐…… 2、国务院副总理张国清：加快制造业数智化转型升 ...

Key Points - 合富中国's stock will resume trading on November 20 after completing an investigation into unusual trading fluctuations, confirming normal business operations and no undisclosed significant matters [1] - 中金公司 plans to merge with 东兴证券 and 信达证券, leading to a suspension of its A-shares starting November 20 due to uncertainties surrounding the merger [1] - 大为股份 is progressing with the transition from exploration to mining rights for its lithium battery project in Hunan, having received necessary approvals [1] - 燕东微's major shareholders plan to reduce their stakes by up to 2.5% through block trades or centralized bidding from December 11, 2025, to March 11, 2026 [2] - 中水渔业's major shareholder reduced its stake to 5% after selling 258.88 million shares [3] - 韵达股份 reported a slight decline in express service revenue for October 2025, totaling 4.495 billion yuan, a year-on-year decrease of 0.88% [4] - 倍杰特 intends to acquire a 55% stake in 大豪矿业 for 224.8 million yuan [4] - 辰奕智能 plans to acquire a 55% stake in 华泽电子 through cash [4] - 赣粤高速's actual controller will change from the provincial transportation department to the provincial state-owned assets supervision and administration commission [5] - 东软集团 received a notification for a 4.2 billion yuan contract for intelligent cockpit controllers from a major domestic automotive manufacturer [5] - 海正药业's subsidiary plans to invest in a pet prescription food project [5] - 龙利得's controlling shareholder plans to increase its stake by at least 56 million yuan [6] - 新兴装备's shareholders plan to reduce their stakes by up to 3.13% [6] - 普洛药业 plans to repurchase shares worth between 180 million and 360 million yuan [6]

Core Viewpoint - The article summarizes important announcements from various companies, highlighting their operational statuses, financial risks, and significant transactions. Group 1: Company Operations and Financial Risks - Aoyuan Meigu's court has allowed the company to continue operations during its restructuring period, but faces risks of bankruptcy and delisting if the restructuring fails [4] - Inspur Software reported a net profit loss of 211.06 million yuan for the first three quarters of 2025, a 123% decline year-on-year, indicating significant performance risks [5] - Hainan Development disclosed that it has been involved in lawsuits totaling 122 million yuan over the past 12 months, which is 11.37% of its latest audited net assets [8] Group 2: Share Buybacks - Haida Group announced its first share buyback, purchasing 137,600 shares for a total of approximately 7.99 million yuan [9] - Guangyu Group completed a share buyback of 10,108,000 shares, amounting to 29.99 million yuan, representing 1.31% of its total share capital [10] - Pro Pharmaceutical plans to repurchase shares worth between 180 million to 360 million yuan for employee incentive plans, targeting a repurchase price not exceeding 23 yuan per share [11] Group 3: Major Contracts and Projects - Han Jian He Shan won a bid for a water supply project worth 388 million yuan, which is expected to significantly impact its revenue [17] - Dafeng Industrial secured a project worth 165.28 million yuan, which represents nearly 9% of its revenue from the previous year [19] - Jiangnan Water signed a contract valued at 368 million yuan for a drainage improvement project, which will positively affect its business performance [20]